Gentris was founded in 2001 and is an established market leader and expert in providing superior quality applied pharmacogenomic (PGx) services in a highly regulated and complex clinical environment. 

Gentris has developed comprehensive and scalable laboratory processes and has provided PGx support domestically and globally for over 1000 Phase I-Phase III clinical trials.

Gentris offers a full spectrum of specialty PGx testing services including:

• >120 Validated Clinical Genotyping Assays
• >30 Validated Gene Expression Assays
• 2000 genotyping assays
• Tumor Profiling
• Custom Assay Development and Validation
• Expertise in Clinical Sample Logistics
• Seamless Integration with CRO Partners
• Nucleic Acid Extraction from Multiple Tissue Types
• Biostorage and Sample Management Services

Gentris also provides high-value consulting to pharmaceutical and biotech companies to guide them through the strategic decisions they will make concerning a PGx program.  We have extensive experience with GLP regulations and with the regulatory agencies in the United States, Europe, and Japan. 

Gentris maintains a competitive edge with its extensive customer base and ensures client satisfaction through technology integrations and strategic partnerships, as well as through its strong pharmacogenomics expertise and know-how. Gentris is located approximately one mile from RDU airport in Morrisville, North Carolina, an area rich in biotechnology industries.  This prime location has abundant resources which allow Gentris to have access to an excellent labor pool as well as supply, reagent, and equipment vendors. 

Gentris has a facility in Japan through an exclusive 10-year partnership with FALCO biosystems based in Kyoto.  Gentris "know-how" was licensed to FALCO to ensure that sample processing would be the same in these two facilities.